Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
The EXPLORER-HCM study: mavacamten for obstructive HCM
View through CrossRef
This video summarizes the underlying cause of hypertrophic cardiomyopathy (HCM), common symptoms of HCM, mechanism of action of mavacamten, and key results of the EXPLORER-HCM trial, which compared mavacamten to placebo in patients with obstructive HCM. The results of the EXPLORER-HCM study were recently published in the The Lancet. A plain language summary of the study has subsequently been published in Future Cardiology and helps patients, their caregivers, patient advocates and healthcare professionals understand the results of the trial.
Title: The EXPLORER-HCM study: mavacamten for obstructive HCM
Description:
This video summarizes the underlying cause of hypertrophic cardiomyopathy (HCM), common symptoms of HCM, mechanism of action of mavacamten, and key results of the EXPLORER-HCM trial, which compared mavacamten to placebo in patients with obstructive HCM.
The results of the EXPLORER-HCM study were recently published in the The Lancet.
A plain language summary of the study has subsequently been published in Future Cardiology and helps patients, their caregivers, patient advocates and healthcare professionals understand the results of the trial.
Related Results
Abstract 4144404: Efficacy of Mavacamten on Echocardiographic Parameters and Cardiac Biomarkers in Hypertrophic Cardiomyopathy Patients: A Systematic Review and Meta-Analysis
Abstract 4144404: Efficacy of Mavacamten on Echocardiographic Parameters and Cardiac Biomarkers in Hypertrophic Cardiomyopathy Patients: A Systematic Review and Meta-Analysis
Introduction:
Mavacamten, a cardiac myosin inhibitor, distinguishes from other pharmacological interventions by addressing not only symptomatic treatment but also targe...
Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy
Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy
Hypertrophic cardiomyopathy is the most common monogenic cardiovascular disease that is caused by sarcomeric protein gene mutations. A hallmark of the most common form of the disea...
ASSA13-06-5 Autosomal Recessive Tansmission of MYBPC3 Mutation Resulted in Malignant Phenotpye of Hypertrophic Cardiomyopathy
ASSA13-06-5 Autosomal Recessive Tansmission of MYBPC3 Mutation Resulted in Malignant Phenotpye of Hypertrophic Cardiomyopathy
Background
Hypertrophic cardiomyopathy (HCM) secondary to mutations in genes encoding sarcomere proteins is most commonly inherited as an autosomal dominant trait...
Mavacamten maintenance dose determination: insights into individualised therapy for hypertrophic cardiomyopathy
Mavacamten maintenance dose determination: insights into individualised therapy for hypertrophic cardiomyopathy
Aims
Mavacamten, the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addresses hypercontractility and left ventric...
The Planet Explorer: Navigating Planetary Sample Data in Spatial Dimensions
The Planet Explorer: Navigating Planetary Sample Data in Spatial Dimensions
Introduction:  Renewed interest in a human return to the Moon has revived the importance of past Apollo missions. Both manned and robotic missions to the Moon provided det...
Assessing Goodness of Fit of Hybrid Choice Models
Assessing Goodness of Fit of Hybrid Choice Models
Recent research in travel behavior has contributed numerous technical developments for the estimation of discrete choice models with latent attributes, including the hybrid choice ...
Overview of Obstructive Hypertrophic Cardiomyopathy
Overview of Obstructive Hypertrophic Cardiomyopathy
Antonis Pantazis, Consultant Cardiologist at the Royal Brompton and Harefield Hospitals and North Middlesex University Hospital in London, UK, and Chairperson of the European Socie...
ACE Genotype Distributions Differ between Sporadic and Familial Hypertrophic Cardiomyopathy
ACE Genotype Distributions Differ between Sporadic and Familial Hypertrophic Cardiomyopathy
This study investigated the frequency of ACE genotypes in sporadic hypertrophic cardiomyopathy (HCM) and compared these frequencies to those found in the general population and in ...